Skip to main content
Premium Trial:

Request an Annual Quote

It's Highly Specific. It's Non-invasive. And It's Got to Be Cheaper, People

The release of a new genetic test in the UK highlights the promise and pitfalls of biomarker-based diagnostics. The test measures the expression of PCA3, a gene linked to prostate cancer, and relies on urine samples instead of blood, according to this report from BBC. The promise: The gene under scrutiny appears to be "a more specific indicator of cancer than PSA," the article says. And the pitfall: But the diagnostic will cost £200, making it "unlikely to be used routinely" with more potential for use in "high-risk patients."


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.